H.C Wainwright Initiates Onconova Therapeutics At Buy

Analysts at H.C Wainwright initiated coverage on

with a Buy rating. The target price for Onconova Therapeutics is set to $6. Onconova Therapeutics shares have dropped 58.91 percent over the past 52 weeks, while the S&P 500 index has surged 13.21 percent in the same period. Onconova Therapeutics' shares closed at $2.26 yesterday.